Literature DB >> 8981889

Hybrid total hip arthroplasty: 7- to 10-year results.

R A Berger1, L R Kull, A G Rosenberg, J O Galante.   

Abstract

One hundred fifty consecutive hybrid total hip arthroplasties in 139 patients were performed using an uncemented hemispheric porous coated acetabular component (HGP-I) with screws and a femoral component (Precoat) cemented with contemporary cementing technique. The average patient age was 67 years (range, 39-85 years). No patients were lost to followup. Eighty-six patients (91 hips) were alive for an average clinical followup of 103 months (range, 84-127 months); 81 hips had corresponding radiographic analysis. The average Harris hip score preoperatively was 47 points and increased to 88 points at followup. Ninety-five percent of patients had absent or slight pain. Aseptic loosening occurred in 2 femoral components (1.3%), 1 of which was revised for secondary osteolysis. Both hips had suboptimal cement mantles (C-2 or D grades). No femoral osteolysis was seen in stable components. Two acetabular components migrated; 1 secondary to preoperative irradiation osteonecrosis and 1 secondary to a bulk autogenous graft. Acetabular osteolysis without loosening developed in 2 patients (1.3%). Using revision and radiographic loosening as the end point, the probability of both components surviving 10 years was 96.9%, 98.6% for the acetabular component, and 98.4% for the femoral component. These results show that hybrid total hip arthroplasty offers excellent clinical function and exceptional 10-year survivorship.

Entities:  

Mesh:

Year:  1996        PMID: 8981889

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  The Current Concepts of Total Hip Arthroplasty.

Authors:  Joong-Myung Lee
Journal:  Hip Pelvis       Date:  2016-12-28

2.  Risk factors for early revision after total hip and knee arthroplasty: National observational study from a surgeon and population perspective.

Authors:  Alex Bottle; Sunny Parikh; Paul Aylin; Mark Loeffler
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.